Loading...

Sensorion SA

ALSEN.PA•EURONEXT
Healthcare
Biotechnology
€0.31
€-0.01(-4.29%)

Sensorion SA (ALSEN.PA) Stock Overview

Explore Sensorion SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.7/100

Key Financials

Market Cap93.8M
P/E Ratio-3.57
EPS (TTM)$-0.09
ROE-0.33%
Fundamental Analysis

AI Price Forecasts

1 Week$0.37
1 Month$0.34
3 Months$0.68
1 Year Target$0.32

ALSEN.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sensorion SA (ALSEN.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 45.81, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.57 and a market capitalization of 93.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

45.81RSI (14)
-0.01MACD
15.35ADX
Stats data is not available for ALSEN.PAStats details for ALSEN.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALSEN.PAAnalyst Recommendations details for ALSEN.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

CEO

Nawal Ouzren

Employees

63

Headquarters

375, rue du Professeur Joseph Blayac, Montpellier

Founded

2015

Frequently Asked Questions

;